Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate whether the sodium–glucose cotransporter 2 inhibitor empagliflozin (EMPA) reduces liver fat content (LFC) in recent-onset and metabolically well-controlled type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: Patients with T2D (n = 84) (HbA1c 6.6 ± 0.5% [49 ± 10 mmol/mol], known disease duration 39 ± 27 months) were randomly assigned to 24 weeks of treatment with 25 mg daily EMPA or placebo. The primary end point was the difference of the change in LFC as measured with magnetic resonance methods from 0 (baseline) to 24 weeks between groups. Tissue-specific insulin sensitivity (secondary outcome) was assessed by two-step clamps using an isotope dilution technique. Exploratory analysis comprised circulating surrogate markers of insulin sensitivity and liver function. Statistical comparison was done by ANCOVA adjusted for respective baseline values, age, sex, and BMI. RESULTS: EMPA treatment resulted in a placebo-corrected absolute change of −1.8% (95% CI −3.4, −0.2; P = 0.02) and relative change in LFC of −22% (−36, −7; P = 0.009) from baseline to end of treatment, corresponding to a 2.3-fold greater reduction. Weight loss occurred only with EMPA (placebo-corrected change −2.5 kg [−3.7, −1.4]; P < 0.001), while no placebo-corrected change in tissue-specific insulin sensitivity was observed. EMPA treatment also led to placebo-corrected changes in uric acid (−74 mol/L [−108, −42]; P < 0.001) and high-molecular-weight adiponectin (36% [16, 60]; P < 0.001) levels from 0 to 24 weeks. CONCLUSIONS: EMPA effectively reduces hepatic fat in patients with T2D with excellent glycemic control and short known disease duration. Interestingly, EMPA also decreases circulating uric acid and raises adiponectin levels despite unchanged insulin sensitivity. EMPA could therefore contribute to the early treatment of nonalcoholic fatty liver disease in T2D.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, the amount of weight loss determined the amount of liver lipid reduction for both empagliflozin [98] and canagliflozin [155] in respective RCTs.”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [98]
In the citing paper
“Notably, weight loss-mediated improvement of MASLD-related steatosis did not necessarily depend on normalization of glycemia in RCTs with caloric restriction or sodium-glucose co-transporter 2 inhibitor (SGLT2I) treatment [97][98][99].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [98]
In the citing paper
“whereas both dapagliflozin and empagliflozin were able to reduce liver lipid content in people with type 2 diabetes with (dapagliflozin [153,154]) or both with and without MASLD (empagliflozin [98]).”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [98]
In the citing paper
“Further, in another RCT, empagliflozin led to a placebocorrected 2.3-fold greater reduction in liver lipid content and a 36 % increase in plasma adiponectin levels in people with type 2 diabetes and short diabetes duration, despite unchanged fasting glycemia and tissuespecific insulin sensitivity [4,98].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [98]
In the citing paper
“Trials in people with T2D (not all with MASLD and some excluding high ALT values) have shown a moderate reduction in liver lipid content with empagli fl ozin, 414,415 dapagli fl ozin 416 and licoglifl ozin.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [415]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Missing data: our view of the state of the art
Schafer, J. L., & Graham, J. W. (2002) · Psychological Methods · doi:10.1037/1082-989x.7.2.147 · Cited by 11,638
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
A short questionnaire for the measurement of habitual physical activity in epidemiological studies
Baecke, J., Burema, J., & Frijters, J. (1982) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/36.5.936 · Cited by 3,945
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Szczepaniak, L. S., Nurenberg, P., Leonard, D., Browning, J. D., Reingold, J. S., Grundy, S., Hobbs, H. H., & Dobbins, R. L. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00064.2004 · Cited by 1,562 · cited 1×
“56% [21]) occurred in 5 (20%) of 25 patients in the EMPA group and 2 (8%) of 24 patients in the placebo group at 24 weeks.”
BackgroundTreatment of NAFLD with diet, physical activity and exercise
Romero-Gómez, M., Zelber-Sagi, S., & Trenell, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.016 · Cited by 1,347 · cited 1×
“02) and relative decrease in LFC (222% [236, 27]; P 5 0.”
BackgroundMetabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
Tilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002
Self-citationDapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Cited by
Items 201–300 of 370
Günhan, H. G., Imre, E., Erel, P., & Ustay, O. (2020) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2020.59 · Cited by 10
Iwamoto, Y., Kimura, T., Dan, K., Iwamoto, H., Sanada, J., Fushimi, Y., Katakura, Y., Shimoda, M., Nogami, Y., Shirakiya, Y., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15548 · Cited by 12
Lee, C., Seto, W., Ieong, K., Lui, D. T. W., Fong, C. H.-Y., Wan, H. Y., Chow, W.-S., Woo, Y. C., Yuen, M., & Lam, K. S. L. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.887 · Cited by 12
“It also takes into consideration anti-diabetic agents with reported beneficial effects in NAFLD, such as pioglitazone, glucagon-like peptide-1 receptor agonists and sodium glucose co-transporter 2 inhibitors [34-37].”
BackgroundGarcía‐Compeán, D., Kumar, R., del Cueto-Aguilera, Á. N., Maldonado-Garza, H. J., & Villarreal‐Pérez, J. Z. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100751 · Cited by 12
Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors
Prandi, F. R., Barone, L., Lecis, D., Belli, M., Sergi, D., Milite, M., Lerakis, S., Romeo, F., & Barillà, F. (2022) · Biomolecules · doi:10.3390/biom12101349 · Cited by 12
Koo, D.-J., & Lee, W. (2022) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2022.4.e17 · Cited by 9
Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models
Kim, D. Y., Chung, K. S., Park, J. Y., & Gee, H. Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114445 · Cited by 9
Katsuyama, H., Hakoshima, M., Iijima, T., Adachi, H., & Yanai, H. (2020) · Journal of Endocrinology and Metabolism · doi:10.14740/jem632 · Cited by 10
“ed protein kinase (AMPK) by inhibiting mitochondrial function and elevating adiponectin levels [16, 20], leading to upregulation of fatty acid (FA) oxidation in skeletal muscle and liver as well as downregulation of FA synthesis in the liver [21, 22].”
BackgroundSelf-citationSato, M., Tamura, Y., Kaga, H., Yamasaki, N., Kiya, M., Kadowaki, S., Sugimoto, D., Funayama, T., Someya, Y., Kakehi, S., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9091154 · Cited by 9
Holleboom, A. G., Francque, S., Cusi, K. J., & Caussy, C. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100424 · Cited by 11
“In an RCT including patients with well-controlled T2DM, empagliflozin treatment demonstrated a significantly higher decrease in liver lipid content compared to placebo but no change in insulin sensitivity assessed by euglycaemic-hyperinsulinaemic clamps was observed [105].”
Abdalla, N., Abo–Elmatty, D. M., Saleh, S., Ghattas, M. H., & Omar, N. N. (2023) · Scientific Reports · doi:10.1038/s41598-023-46288-5 · Cited by 9
Esmaeili, A., Azar, R. P., Hosseiniazar, M. M., & Gharabagh, L. H. (2024) · Journal of General and Family Medicine · doi:10.1002/jgf2.723 · Cited by 10
Mechanisms of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure
Wei, J., & Du, J. (2023) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2023.0028 · Cited by 10
Impact of tofogliflozin on hepatic outcomes: a systematic review
Pathak, M., Parveen, R., Khan, P. M., Saha, N., & Agarwal, N. B. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03537-w · Cited by 8
Guía de práctica clínica multidisciplinar de manejo de la esteatosis hepática metabólica
Romero‐Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F. J., Cañones, P., et al. (2025) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2025.502442 · Cited by 9
Tan, Y., Qu, W., Zhao, J., Ma, Y., Zhang, Q., Gao, H., Zhen, Q., Wang, Y., Peng, Y., Liu, F., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101680 · Cited by 7
State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
Cho, Y., & Lee, Y. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.102 · Cited by 8
“[70] Phase 4 randomized, double-blind, placebo-controlled Empagliflozin: SGLT2i 1:1 Empagliflozin 25 mg Placebo 6 months (24 weeks) Type 2 diabetes (BMI <45 kg/m(2), known T2DM duration ≤7 years, HbA1c of 6%–8%, and no previous antihyperglycemic treatment) The change in liver fat measured by MRS Improved: Reducing liv…”
MethodAlfayez, A. I., Alfallaj, J. M., Mobark, M. A., Alalwan, A. A., & Alfayez, O. M. (2023) · Current Diabetes Reviews · doi:10.2174/1573399820666230525150437 · Cited by 8
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease Cross Talk
Nysather, J. A., Kaya, E., Manka, P. P., Gudsoorkar, P. S., & Syn, W. (2023) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2023.04.001 · Cited by 8
Wang, D., Mao, Y., Yang, Y., Wang, T.-Y., Zhu, P., He, S., & Chen, X. (2022) · Journal of Diabetes Research · doi:10.1155/2022/4491900 · Cited by 8
Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma
Jeong, S., Shin, W.-Y., & Oh, Y. H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1150360 · Cited by 9
Pieralice, S., Amendolara, R., Berna, V., Manganaro, G., Zurru, A., D’Onofrio, L., Risi, R., Alfonsi, M., Maddaloni, E., & Buzzetti, R. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s528569 · Cited by 9
Gál, A. R., Szokodi, I., Vizvári, Z., Győrfi, N., Vereczkei, A. G., Petykó, Z., Karádi, Z., & Tóth, A. (2026) · Antioxidants · doi:10.3390/antiox15060710 · Cited by 6
Current Treatment Options, Including Diet, Exercise, and Medications
Noureddin, M., & Abdelmalek, M. F. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.008 · Cited by 7
Inflammation in Steatotic Liver Diseases: Pathogenesis and Therapeutic Targets
Qian, S., Wang, X., Chen, Y., Zai, Q., & He, Y. (2024) · Seminars in Liver Disease · doi:10.1055/a-2338-9261 · Cited by 7
Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms
Lee, H. A., Lee, H. A., & Kim, H. Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-79428-6 · Cited by 7
Koullias, E., Papavdi, M., Koskinas, J. S., Deutsch, M. J., & Thanopoulou, A. C. (2025) · Cureus · doi:10.7759/cureus.76716 · Cited by 13
Hupa‐Breier, K. L., Schenk, H. J., Campos-Murguía, A., Wellhöner, F., Heidrich, B., Dywicki, J., Hartleben, B., Böker, C., Mall, J. W., Terkamp, C., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102104 · Cited by 8
New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
Li, J., Zhou, L., & Gong, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.903902 · Cited by 6
Min, C., Fu, T., Tan, W., Wang, T., Du, Y., & Huang, X. (2022) · Biomedical Reports · doi:10.3892/br.2022.1591 · Cited by 6
Gracen, L., Muthukumara, W., Aikebuse, M., Russell, A. W., O’Beirne, J. P., Irvine, K. M., Williams, S., Puri, G., Valery, P. C., Hayward, K. L., et al. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101142 · Cited by 6
Procyk, G., Jaworski, J., Gąsecka, A., Filipiak, K. J., & Borovac, J. A. (2024) · Advances in Medical Sciences · doi:10.1016/j.advms.2024.09.001 · Cited by 7
Rohbeck, E., Hasse, B., Koopmans, G. C., Romero, A., Belgardt, B., Roden, M., Eckel, J., & Romacho, T. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14719 · Cited by 6
Self-citationCarretero‐Gómez, J., Ena, J., Ripoll, J. M. S., Carrasco-Sánchez, F. J., Gómez‐Huelgas, R., Rojo, J. M. C., Tembra, M. S., Rueda, J. J. C., & Arévalo‐Lorido, J. C. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1965563 · Cited by 6
Khalil, I., Hossain, M. I., Akter, M., & Al‐Badri, S. G. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003658 · Cited by 5
“Empagliflozin’s HbA1c reduction aligns with Kahl et al ’s findings, which reported a 0.7% decrease in HbA1c, attributed to improved insulin sensitivity and reduced glucotoxicity [ 17 ] .”
InfluentialJia, X., Wang, S., Wang, J., Ding, Y., Li, M., Lin, Y., Zheng, R., Huang, F., Wei, H., Hu, C., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03008-9 · Cited by 5
“Early identification of high-risk individuals during the prediabetic stage is crucial—par-ticularly for the HBP and HLP_SCR_ALT subtypes, which exhibit the highest T2D and kidney event risks and may benefit most from early interventions such as blood pressure and fatty liver management [46, 47].”
Hirose, K., Nakanishi, K., Tullio, M. R. D., Homma, S., Sawada, N., Yoshida, Y., Hirokawa, M., Koyama, K., Kimura, K., Nakao, T., et al. (2023) · European Heart Journal Open · doi:10.1093/ehjopen/oead108 · Cited by 5
“Given the strong predictive value of LVGLS for subsequent HF, evaluation of LVGLS could possibly aid in HF risk stratification in individuals with NAFLD, even in the absence of overt cardiac disease, because approximately one-third of patients with NAFLD had abnormal LVGLS. 36 Future studies are warranted to investiga…”
BackgroundInfluentialZhang, Z., Bao, K., Liu, J., Jiang, C., Ji, C., Han, J., Zhou, G. F., Liu, X., Liu, T., Gao, J., et al. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01489-4 · Cited by 5
“Existing studies illustrate liver fat as the most rapidly mobilized ectopic fat stored during weight loss interventions [32, 33], which might indicate the role of liver fat content as a sensitive indicator of metabolic status.”
BackgroundPersonalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?
Abdul‐Ghani, M. A., & DeFronzo, R. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1967319 · Cited by 5
Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis
Kahl, S., Pützer, J., & Roden, M. (2022) · Seminars in Liver Disease · doi:10.1055/s-0041-1732354 · Cited by 5
Self-citationNon-alcoholic fatty liver disease in patients with type 2 diabetes mellitus
Mankieva, E., & Ивановна, К. Е. (2023) · Russian Journal of Evidence-Based Gastroenterology · doi:10.17116/dokgastro202312041103 · Cited by 5
Yanai, H., Hakoshima, M., & Katsuyama, H. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4019 · Cited by 6
Self-citationEmerging Therapies and Therapeutic Targets for Composite Liver Disease: NASH
Sobhia, M. E., Kumari, S., Kumar, H., Gandhe, A., Kaushik, D., Kumar, H., Jain, J., Ankita, A., Mallick, M., Pavani, B., et al. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230714113808 · Cited by 4
Albai, O., Braha, A., Timar, R. Z., Lazăr, S., Popescu, S. D., & Timar, B. (2025) · Medicina · doi:10.3390/medicina61101850 · Cited by 4
Naumova, A. V., Cunha, G. M., Kim, N. J., Lu, J., Isquith, D. A., Chu, B., Maynard, C. C., Mahdavi, A., Firoozeh, N., Ordovas, K. G., et al. (2026) · Obesity · doi:10.1002/oby.70134 · Cited by 5
“Few studies have also assessed liver fat using MRI, [22].”
Lean metabolic dysfunction-associated steatotic liver disease: Current insights and knowledge gaps
Praveen Sandeep Raj, R., John, R., Manoharan, F., Janeela, A. M., Goel, A., & Kapoor, N. (2026) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2026.102107 · Cited by 6
Newer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
Stefanakis, K., Karakasis, P., Vasdeki, D., Popovic, D. S., Patoulias, D., Rizzo, M., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag022 · Cited by 6
Васильевна, Ц. О., Тимощенко, О. В., Tuzovskaia, O. V., Latyntseva, L. D., & Nikolaev, К. Y. (2022) · Сибирский научный медицинский журнал · doi:10.18699/ssmj20220601 · Cited by 4
Zhu, L., Chen, Y., Li, Q., Wang, Z., Jiao, S., Zheng, S., Yang, F., & Sun, Y. (2024) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2023.0095 · Cited by 4
“Recent RCTs have further highlighted the potential benefits of SGLT-2 inhibitors in individuals with NAFLD and NASH, as well as obesity and type 2 diabetes, through the imaging assessment of hepatic steatosis with MRI-based techniques [34].”
BackgroundComparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients
Yun, B., Oh, J., Park, H., Lee, J., Kim, B. K., & Yoon, J. (2025) · Liver International · doi:10.1111/liv.70060 · Cited by 5
“Moreover, several studies have also highlighted the hepatic benefits of SGLT2i on LRE, including steatotic liver disease, liver fibrosis and HCC in patients with T2DM [12, 13].”
Calapod, O. (2020) · FARMACIA · doi:10.31925/farmacia.2020.5.2 · Cited by 4
“Moreover, recent diabetes management guidelines suggest that an SGLT-2 inhibitor (empagliflozin) may lower hepatic fat content in patients with T2DM and can be used as the first-line treatment in NAFLD [21].”
BackgroundBandyopadhyay, S. K., Samajdar, S. S., Chaudhuri, S., & Das, S. (2024) · Hospital Practice · doi:10.1080/21548331.2024.2412513 · Cited by 3
7. Management of metabolic dysfunction-associated steatotic liver disease (MASLD) in type 2 diabetes
Colagiuri, S., & Ceriello, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112151 · Cited by 3
Matuszewski, W., Tomaszek, L., Szklarz, M., Górny, J. M., Kordas, B., Rutkowska, J., & Juranek, J. K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186348 · Cited by 4
“Additionally, an important trial demonstrated that a daily dose of 25 mg empagliflozin significantly reduced liver fat content, as assessed by magnetic resonance spectroscopy [71,72].”
Laitinen, A., Käräjämäki, A., Käräjämäki, A. J., Kurki, S. H., Hakaste, L., Asplund, O., Hultman, J., Lahti, K., Lehtovirta, M., Ahlqvist, E., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70983 · Cited by 3
Khalil, I., Hossain, M. I., & Akter, M. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.08.007 · Cited by 4
Hamzah, K. A., Shweliya, M. A., Kurmasha, Y. H., Ahmed, M. J., Habib, A., Kamel, A. I. I., Rashid, Z., Shimal, A. A., Moghazy, M., Fahem, F., et al. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02084-x · Cited by 3
Laurence, A., Gandhi, S., Nylén, E., & Sen, S. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.02.011 · Cited by 3
Mao, X., Fan, H., Yuen, M.-F., Cheung, R. C., Seto, W., & Nguyen, M. H. (2026) · Hepatology · doi:10.1097/hep.0000000000001771 · Cited by 6
da Rocha, K. V., Bueno, J. V. D. M., Neves, P. H. G., de Almeida, P. P. A. C., Bueno, A. C. D. M., Cabral, M. D., Gomes, G. M., & Vogas, K. B. (2023) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v9i8.10795 · Cited by 3
Omari, M. B., Naseri, S., & Hassan, A. J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s448670 · Cited by 3
Choi, R., Vemuri, J. P., Poloju, A., Raj, R., Mehta, A., Asgharpour, A., Siddiqui, M. S., & Majety, P. (2025) · Endocrines · doi:10.3390/endocrines6020027 · Cited by 4
“In phase 4 and phase 3 RDBPCTs, empagliflozin led to significant LFC reductions measured by MRS ( − 22%, p = 0.009) and weight loss ( p 0.001), particularly in male patients [60].”
InfluentialLuong, T. V., Tran, H., Thi, B. N. C., Vu, H. M., Le, T., Le, T., Thi, H. N., Nguyen, H. M., Doan, T. C., Ho, A. B., et al. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i7.107751 · Cited by 5
Kawahara, T., Toda, M., Kanagawa, M., Toyama, N., Suzuki, G., Kawahara, C., & Inazu, T. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s547088 · Cited by 4
“Furthermore, SGLT-2is have been shown to enhance insulin sensitivity by increasing adiponectin levels 33 and to promote glucagon-like peptide 1 secretion, 34,35 both of which may contribute to the improvement of MASLD.”
Kostitska, I. O., Protas, N., & Petrovska, L. (2023) · Diabetes Obesity Metabolic Syndrome · doi:10.57105/2415-7252-2023-5-01 · Cited by 3
SOKOLOVA, L. K., Vm, P., Ковзун, О. І., Левчук, Н. І., Пушкарьов, В., Sokolova, A. M., Furmanova, O. V., & Tronko, M. D. (2023) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2023.4.10 · Cited by 4
Tao, S., Guo, S., & Tong, N. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2952 · Cited by 2
“21 The beneficial effect of SGLTis on the development and progression of NAFLD seems to be directly mediated through the regulation of various processes, including endoplasmic reticulum stress, oxidative stress, low-grade inflammation, auto-phagy, and apoptosis.”
Vašura, A., Machytka, E., Urban, O., Macháčková, J., Pavliska, L., Berka, Z., Švagera, Z., & Bužga, M. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101765 · Cited by 2
Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects
Chadwick, J., Berry, C., Carpenter, M. A., Gulati, G., Heck, S. L., Hinterberg, M., Holman, R. R., Lee, M. M. Y., Omland, T., Paterson, C., et al. (2025) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70077 · Cited by 3
Ko, Y., Hur, M. H., Park, Y., Park, J., Shin, H., Lee, Y. B., Cho, E. J., Lee, J., Yu, S. J., Yoon, J., et al. (2025) · Gut and Liver · doi:10.5009/gnl240616 · Cited by 2
Caturano, A., Galiero, R., Simeon, V., Acierno, C., Nilo, D., Marrone, A., Trotta, M. C., Vetrano, E., Sardu, C., Russo, V., et al. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104284 · Cited by 2
Lipid metabolism disorders in metabolic syndrome
Polyakova, E. A. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6539 · Cited by 1
Choi, J., Fulop, D., Nguyen, V. H., Przybyszewski, E. M., Song, J., Carroll, A., Michta, M., Almazan, E., Simon, T. G., & Chung, R. T. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0825 · Cited by 12
AlHussaini, K. I. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1712586 · Cited by 2
Moral, K., Koçak, E., Kablan, S. E., Nemutlu, E., Şendur, H. N., Cerit, M. N., Yalçın, M. M., Bilican, G., Cindoruk, M., Karakan, T., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-44786-w · Cited by 2
“This finding suggests that the beneficial effects on hepatic steatosis may extend beyond glycemic control and weight reduction alone 8 .”
Aliabadi, M., Soleimani, A. A., Taheripak, G., Nourbakhsh, M., & Meshkani, R. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02013-3 · Cited by 2
“Hepatoprotective and anti-inflammatory actions have been consistently reported [ 9, 10 ].”
Parveen, R., Hussain, S., Saini, S., Khan, P., Saha, N., & Nidhi, N. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2360078 · Cited by 2
“…hypoglycemic drugs, including metformin, sitagliptin, vildagliptin (dipeptidyl peptidase-4 inhibitors), and sodium-glucose cotransporter-2 (SGLT-2) inhibitors like dapagliflozin, canagliflozin, empagliflozin, and ipragliflozin, have demonstrated improvements in liver fat and liver enzymes [28–32].”
BackgroundClinical management of MASLD and MASH—An overview
Horn, P., & Newsome, P. N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00019-4 · Cited by 2
Vincenzo, A. D., Russo, L., Doroldi, C. G., Vettor, R., & Rossato, M. (2021) · Exploration of Medicine · doi:10.37349/emed.2021.00049 · Cited by 2
Левчук, Н. І., Kovzun, O., Pushkarev, V. M., & Tronko, M. D. (2023) · JOURNAL OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE · doi:10.37621/jnamsu-2023-1-2-1 · Cited by 2
“Також є дані, що емпагліфлозин знижує вміст жиру в печінці в осіб з добре контрольованим ЦД2 [62].”
Dyslipidemia in Metabolic Syndrome
Toh, S.-A. E. S., & Lee, M. H. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_58-1 · Cited by 4
Alsarkhi, L. N., Eda, S., Abdul, R. H. M., Hussaini, H., Fadeyi, O. A., Chaudhari, S. S., Rauf, M. A., & Allahwala, D. (2025) · Cureus · doi:10.7759/cureus.90205 · Cited by 5
“Simultaneously, its pleiotropic effects include enhanced insulin sensitivity, reduced hepatic gluconeogenesis, and increased fatty acid oxidation, mechanisms that directly benefit hepatic steatosis and metabolic dysfunction [6,7].”
Shinozaki, S., Tahara, T., Miura, K., Lefor, A. K., & Yamamoto, H. (2023) · Life · doi:10.3390/life13061327 · Cited by 6
“A Japanese double-blind, placebo-controlled phase II RCT of pemafibrate 0.1 mg twice daily for 72 weeks reported that pemafibrate significantly improved liver enzyme levels without Life 2023, 13, 1327 7 of 12 changing body weight.”
BackgroundResultInfluentialHígado graso no alcohólico: certezas e incertidumbres de una epidemia silenciosa
Ballerga, E. G., Curia, A., & Cusi, K. J. (2020) · Acta gastroenteorológica latinoamericana/Acta gastroenterológica latinoamericana · doi:10.52787/zojs3069 · Cited by 10
Zhao, Y. (2024) · International Journal of Public Health and Medical Research · doi:10.62051/ijphmr.v1n1.05 · Cited by 1
“…placebo-controlled Phase IV clinical trial further confirmed the efficacy of enoglizin in reducing liver fat in T2DM patients with NAFLD and found that Enoglizin reduced circulating uric acid and increased adiponectin levels, although it did not significantly alter insulin sensitivity [37].”
BackgroundMultidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis
Romero‐Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F. J., Cañones, P., et al. (2025) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2025.502442 · Cited by 6
Лазебник, Л. Б., Туркина, С. В., & Golovanova, E. V. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-230-10-11-35 · Cited by 1
Evidence-Based Management of MASLD: GRADE Evaluation of Pharmacological Therapies
Karavia, E. A., Pittaras, A. E., Andreopoulou, O., Hatziri, A., Makrydimitri, A., Anagnostopoulos, D., Vareltzis, P. K., & Kypreos, K. E. (2026) · Pharmaceuticals · doi:10.3390/ph19040605 · Cited by 1
“Randomized trials demonstrated reductions in liver fat and improvement in liver enzymes compared with placebo, including studies in non-diabetic populations [26,27] GRADE assessment: Moderate quality of evidence.”
Hu, J., Chang, M., Huang, T.-J., Liu, N., & Tang, J. (2026) · Biomedicines · doi:10.3390/biomedicines14051168 · Cited by 1
“Beyond glycemic control, these agents reduce body weight, improve insulin resistance, and may ameliorate hepatic steatosis, metabolic inflammation, oxidative stress, and fibrogenic signaling [11,12].”
Maier, G. A., Hofmann, R. A., Roden, M., Rathmann, W., & Kuß, O. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71023 · Cited by 1
Self-citationAbdalla, M. H. A., Khamees, M. E. S., Gehani, A.-L., Ibrahim, A. I. M., Yousif, M. Y., Kheir, N., Alqasem, S. M. Q., & Ahmed, A. (2026) · Cureus · doi:10.7759/cureus.102618 · Cited by 1
“Of the 32 included primary studies, 23 were interventional studies [ 15-37 15-37 ], The most frequently evaluated SGLT2 inhibitors were empagliflozin, dapagliflozin, and canagliflozin, whereas ipragliflozin and luseogliflozin were examined less often.”
Uric Acid in Metabolic Dysfunction‐Associated Steatotic Liver Disease
Wang, R., Liu, Z., Lin, J., Zhang, W., Liu, X., & Zhang, T. (2026) · Portal hypertension & cirrhosis · doi:10.1002/poh2.70043 · Cited by 2
PLAKIDA, A. L., Юшковська, О., & Sierpińska, L. E. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i3.113284 · Cited by 1
Xue, L., Wang, X., & Mao, J. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1808135 · Cited by 1
Confounding Metabolic Therapies and Weight Dynamics in Evaluating Essential Phospholipids for MASLD
Lin, Y., & Song, Y. (2026) · Liver International · doi:10.1111/liv.70689 · Cited by 1
“We know these drug classes can drastically reduce both HbA1c and liver fat on their own [2, 3].”
Davies, M. J., Aroda, V. R., Bajaj, M. S., ElSayed, N. A., Giorgino, F., Green, J., Kalyani, R. R., Maruthur, N. M., Mathieu, C., Rosas, S. E., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06855-7 · Cited by 1
Ткач, С. М., & Dogotar, V. B. (2023) · Clinical endocrinology and endocrine surgery · doi:10.30978/cees-2023-2-34 · Cited by 1
Teplyuk, D. A., Kaisina, A. A., Ibragimova, S. I., Bestavashvili, A., Тинькова, И. О., Pashkova, E. Y., Kaibullayeva, J. A., Nersesov, A., & Pavlov, C. S. (2023) · Consilium Medicum · doi:10.26442/20751753.2023.5.202272 · Cited by 2
NAFLD and type 2 diabetes: A practical guide for the joint management
Genua, I., Iruzubieta, P., Rodríguez-Duque, J. C., Pérez, A., & Crespo, J. (2023) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2022.12.010 · Cited by 1
Khwaldeh, A., Al‐Sawalha, N. A., Aljabali, S. M., Shraideh, Z. A., Ababneh, S., & Bdeir, R. (2023) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2787 · Cited by 1
Metadata
- Authors
- Kahl, S., Gancheva, S., Straßburger, K., Herder, C., Machann, J., Katsuyama, H., Kabisch, S., Henkel, E., Kopf, S., Lagerpusch, M., Kantartzis, K., Kupriyanova, Y., Markgraf, D., van Gemert, T., Knebel, B., Wolkersdorfer, M. F., Kuss, O., Hwang, J.-H., Bornstein, S. R., Kasperk, C., Stefan, N., Pfeiffer, A., Birkenfeld, A. L., & Roden, M.
- Affiliations
- Deutsches Diabetes-Zentrum e.V. (DE)
- German Center for Diabetes Research (DE)
- GWT-TUD GmbH (Germany) (DE)
- University Hospital Heidelberg (DE)
- German Center for Diabetes Research, München-Neuherberg, Germany
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich-Heine University, Düsseldorf, Germany
- Landesapotheke Salzburg, Salzburg, Austria
- Paul Langerhans Institute Dresden (DE)
- Corresponding author
- Roden, Michael
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-09-20
- Volume
- 43
- Issue
- 2
- Pages
- 298-305
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2973671909
- Semantic Scholar
- d30e2aeb028f87844806b2c67eeca77b51e7e36a
- Cited by
- 360
- References
- 43
- Citations by year
- 2026: 47 · 2025: 59 · 2024: 58 · 2023: 59 · 2022: 54 · 2021: 46 · 2020: 35 · 2019: 1
- FWCI
- 27.61
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Site cant be reached (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- German Diabetes Center
- German Federal Ministry of Health
- German Center for Diabetes Research
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- empagliflozin, SGLT2 inhibitors, type 2 diabetes, liver fat, hepatic steatosis, non-alcoholic fatty liver disease, insulin sensitivity, uric acid, high molecular weight adiponectin, weight loss, glycemic control, recent-onset diabetes, isotope dilution
- MeSH terms
- Adipose Tissue, Aged, Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Germany, Glucosides, Humans, Hypoglycemic Agents, Insulin Resistance, Liver, Male, Middle Aged, Placebos, Weight Loss, Down-Regulation, Adiposity, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.